AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29115994
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine administered to assess drug metabolizing enzymes activity.
Trial: 29119917
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli PNP delivered via recombinant adenoviral vector followed by systemic administration of fludarabine phosphate
Trial: 29121278
Drug: Ketamine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine and less volatile anaesthetic co-administration
Trial: 29121645
Drug: Dasatinib treatment
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib treatment for a median of nine months
Trial: 29121645
Drug: Dasatinib treatment
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib treatment
Trial: 29121934
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg/day for 12 weeks
Trial: 29123425
Drug: tolvaptan (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolvaptan (60-120 mg/d)
Trial: 29124456
Drug: Exemestane with
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane with low-dose oral cyclophosphamide
Trial: 29124506
Drug: Albuterol after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol after biofeedback sessions
Trial: 29124506
Drug: Budesonide (high-potency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (high-potency inhaled steroid)
Trial: 29124992
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.15-mg/kg bolus with continuous infusion at 2 µg/kg/min)
Trial: 29126426
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants in the maxilla (six implants each, loaded within 24 hours, definitive restoration after 20-24 weeks)
Trial: 29126426
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants in the maxilla
Trial: 29126871
Drug: Lumacaftor/ivacaftor (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor/ivacaftor (full dose)
Trial: 29126871
Drug: Lumacaftor/ivacaftor (half
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor/ivacaftor (half dose)
Trial: 29126871
Drug: Lumacaftor/ivacaftor (half
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor/ivacaftor (half dose increased to full dose)
Trial: 29127195
Drug: Microcatheter contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcatheter contrast injection (MCI) prior to stent retriever deployment
Trial: 29128389
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic therapy (IAT); mean duration 7.8 days; most patients received monotherapy (72.5%)
Trial: 30774399
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic therapy (IAT)
Trial: 29128828
Drug: Diprospan (betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprospan (betamethasone dual-acting formulation) administered via single-dose intramuscular injection
Trial: 29129018
Drug: BIAsp 30
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BIAsp 30 once daily (OD), with the possibility of stepwise treatment intensification up to BIAsp 30 three times daily (TID)
Trial: 29129018
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine OD, with the possibility of stepwise treatment intensification with insulin aspart up to TID
Trial: 29132341
Drug: Sinovial H-L®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinovial H-L® (hybrid formulation of hyaluronic acid)
Trial: 29133316
Drug: NKR-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NKR-2 treatment administered three times with a 2-week interval between each administration.
Trial: 29133513
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) 10 mg/kg IV every 2 weeks combined with Vorinostat (VOR) 400 mg p.o. daily for 7 days on, 7 days off, in a 28-day cycle
Trial: 29134606
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (500 or 1000 mg) as intravenous infusions
Trial: 29134606
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (500 or 1000 mg)
Trial: 29134664
Drug: Ruxolitinib BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles
Trial: 29134664
Drug: Azacytidine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacytidine 25 mg/m2
Trial: 29135575
Drug: Standard antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiretroviral therapy
Trial: 29136201
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg monotherapy
Trial: 29136201
Drug: Selumetinib 25
RxNorm normalized name: selumetinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib 25 mg plus docetaxel 60 mg/m2
Trial: 29136201
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg plus docetaxel 60 mg/m2
Trial: 29136201
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (selumetinib plus docetaxel)
Trial: 29136201
Drug: Selumetinib 50
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 50 mg monotherapy
Trial: 29136317
Drug: Belatacept/sirolimus immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belatacept/sirolimus immunotherapy
Trial: 29137560
Drug: Abstinence-contingent monetary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence-contingent monetary incentives added to cessation treatments (PV only, PV+Q, PV+CBT) for four weeks after a quit attempt.
Trial: 29137560
Drug: Prescriber visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriber visit for pharmacotherapy only (PV only).
Trial: 29137560
Drug: Prescriber visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriber visit and telephone cognitive-behavioral therapy (PV+CBT).
Trial: 29138320
Drug: RTS,S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S vaccine (recombinant circumsporozoite protein-based vaccine)
Trial: 29138340
Drug: Chimeric Antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric Antigen Receptor-Modified T Cells
Trial: 29138569
Drug: Fluvoxamine (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50-300 mg/day for 90 days)
Trial: 29138986
Drug: Secukinumab 10
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8)
Trial: 29138986
Drug: Secukinumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (both dose groups)
Trial: 29139135
Drug: Quizartinib 60
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 60 mg/d for 7 days (DL1; n=6)
Trial: 29139135
Drug: Quizartinib 60
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 60 mg/d for 14 days (DL2; n=7)
Trial: 29139135
Drug: Quizartinib 40
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 40 mg/d for 14 days (DL-1; n=6)
Trial: 29139135
Drug: Quizartinib in
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib in combination with SOC chemotherapy
Trial: 29140548
Drug: SANGUINATE (SG)
RxNorm normalized name: sanguinarine
DrugBank: Pegylated carboxyhemoglobin (bovine) (DB17720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SANGUINATE (SG) infusion, 320 mg/kg, three weekly infusions
Trial: 29140548
Drug: SANGUINATE (SG)
RxNorm normalized name: sanguinarine
DrugBank: Pegylated carboxyhemoglobin (bovine) (DB17720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SANGUINATE (SG) infusion
Trial: 29140978
Drug: 8-item Morisky
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-item Morisky Medication Adherence Scale (MMAS-8)
Trial: 29141662
Drug: Combined autologous
RxNorm normalized name: chondrocytes, autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined autologous adipose-derived mesenchymal stem cells (AT-MSCs) and hyaluronic acid (HA) derivative, single intradiscal injection at a dose of 2 × 10.
Trial: 29142066
Drug: SGN-CD123A, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-CD123A, an antibody-drug conjugate targeting CD123
Trial: 29142375
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg for 7 days)
Trial: 29142987
Drug: Heparin-avoidance hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-avoidance hemodialysis protocol using airless dialysis tubing
Trial: 29142987
Drug: Heparin-avoidance hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-avoidance hemodialysis protocol
Trial: 29143287
Drug: Lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid (LA) 1200 mg oral administration
Trial: 29143919
Drug: iGlarLixi (fixed-ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi (fixed-ratio combination of insulin glargine U100 + lixisenatide)
Trial: 29143919
Drug: iGlar (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlar (insulin glargine U100)
Trial: 29144985
Drug: Rigosertib (650-1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigosertib (650-1700 mg/m2) administered via continuous intravenous infusion for 3-7 days
Trial: 29145039
Drug: SAR125844 (MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR125844 (MET kinase inhibitor) at a maximum tolerated dose (MTD) of 570 mg/m
Trial: 29145895
Drug: hs-cTnT ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT ≥ 0.02 µg/l
Trial: 29145895
Drug: hs-cTnI ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnI ≥ 5.5 ng/l
Trial: 29146409
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy (20 to 120 mg/day)
Trial: 29146409
Drug: Lurasidone adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone adjunctive therapy with lithium or valproate (20 to 120 mg/day)
Trial: 29147617
Drug: hu3F8 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu3F8 monoclonal antibody
Trial: 29149283
Drug: RotaTeq vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq vaccine after first dose
Trial: 29149283
Drug: RotaTeq vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq vaccine after second dose
Trial: 29149283
Drug: RotaTeq vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RotaTeq vaccine after third dose
Trial: 29149914
Drug: Motivational interviewing-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing-based brief intervention (MIBI) as an adjunct to usual care
Trial: 29150536
Drug: Cessation medications
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cessation medications
Trial: 29150844
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied GSK2981278 ointment
Trial: 29153636
Drug: Intensified medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified medical therapy for elevated LDH
Trial: 29153775
Drug: Weekly Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly Paclitaxel (90 mg/m²), Carboplatin, and Bevacizumab
Trial: 29153823
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if LDL-C ≥70 mg/dL at week 8)
Trial: 29153856
Drug: Viscous soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscous soluble fiber supplementation (median dose of 8.7 g/day, range 1.45-30 g/day)
Trial: 29153976
Drug: Pharmacoscopy-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacoscopy-guided treatment
Trial: 29155313
Drug: Deferasirox at
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox at an initial dose of 10 mg/kg/day, with up-titration to a maximum of 20 mg/kg/day for 52 weeks.
Trial: 29155313
Drug: Deferasirox treatment
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox treatment
Trial: 29155991
Drug: PAS-LAR 60
RxNorm normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS-LAR 60 mg monotherapy
Trial: 29155991
Drug: PAS-LAR 60
RxNorm normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAS-LAR 60 mg with 50% reduced pegvisomant dose
Trial: 29155991
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PAS-LAR and pegvisomant
Trial: 29156708
Drug: Refametinib in
RxNorm normalized name: Refametinib
DrugBank: Refametinib (DB06309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refametinib in combination with copanlisib
Trial: 29156708
Drug: Refametinib in
RxNorm normalized name: Refametinib
DrugBank: Refametinib (DB06309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refametinib in combination with lapatinib
Trial: 29156802
Drug: Pemetrexed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed plus carboplatin followed by pemetrexed maintenance therapy
Trial: 29157306
Drug: 9-peptide breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-peptide breast cancer vaccine plus poly-ICLC
Trial: 29158179
Drug: Definite hemostatic
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definite hemostatic treatment (alone or in combination with surgery, chemotherapy, radiotherapy, or radiologic embolization)
Trial: 29158365
Drug: Capecitabine 850
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 850 mg/m², Oxaliplatin, Celecoxib with concurrent radiation therapy
Trial: 29158367
Drug: Necuparanib 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib 0.5 mg/kg + gemcitabine
Trial: 29158367
Drug: Necuparanib 1
RxNorm normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib 1 mg/kg + gemcitabine
Trial: 29158367
Drug: Necuparanib 2
RxNorm normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib 2 mg/kg + nab-paclitaxel + gemcitabine
Trial: 29158367
Drug: Necuparanib 4
RxNorm normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib 4 mg/kg + nab-paclitaxel + gemcitabine
Trial: 29158367
Drug: Necuparanib 5
RxNorm normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib 5 mg/kg + nab-paclitaxel + gemcitabine
Trial: 29158367
Drug: Necuparanib 6
RxNorm normalized name: Necuparanib
DrugBank: Necuparanib (DB16251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necuparanib 6 mg/kg + nab-paclitaxel + gemcitabine
Trial: 29158421
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy in urban hospitals (2001: 54%, 2011: not specified)
Trial: 29158421
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy in rural hospitals (2001: 57%, 2011: not specified)
Trial: 29158913
Drug: Video-based family-oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-based family-oriented treatment for peripartum depression
Trial: 29159083
Drug: Canagliflozin 50
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 50 mg BID
Trial: 29159083
Drug: Canagliflozin 150
RxNorm normalized name: canagliflozin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 150 mg BID
Trial: 29159458
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa 4.0 mg/kg/week
Trial: 29159458
Drug: Combined dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dosage groups (2.0 mg/kg/week and 4.0 mg/kg/week)
Trial: 29159476
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) administered as part of the FOLFOX regimen
Trial: 29159476
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) dosage per kg lean body mass (LBM)
Trial: 29159476
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) dosage for hematological toxicities
Trial: 29160301
Drug: Citalopram/Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram/Escitalopram treatment
Trial: 29162063
Drug: Not on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not on anti-retroviral therapy at baseline
Trial: 29162134
Drug: Anastrozole monotherapy
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole monotherapy
Trial: 29162718
Drug: Fluticasone hydrofluoroalkane
RxNorm normalized name: HYDROFLUOROALKANE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone hydrofluoroalkane inhaled via pMDI with no delay between shaking and actuation
Trial: 29164334
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (1 µg/kg) test before extubation
Trial: 29166901
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen prescription
Trial: 29167744
Drug: Daily parental
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily parental ATS reports
Trial: 29169399
Drug: PReDicT Test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PReDicT Test guided treatment
Trial: 29170088
Drug: Mifepristone (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites)
Trial: 29171941
Drug: Extracorporeal cellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal cellular therapy (ELAD) plus standard of care (SOC) for 3-5 days
Trial: 29174484
Drug: Glucocorticoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid treatment for 1 year or longer
Trial: 29174484
Drug: No glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucocorticoid treatment or cumulative treatment duration of less than 1 month
Trial: 29174546
Drug: Ledipasvir and
RxNorm normalized name: Ledipasvir and Sofosbuvir Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir and Sofosbuvir (90 mg ledipasvir + 400 mg sofosbuvir, once daily for 12 weeks)
Trial: 29174612
Drug: Antituberculosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculosis treatment
Trial: 29176494
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) dosing between birth and 6 months (average 1882 LU/kg per meal, range: 492-3727)
Trial: 29176494
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) dosing between 6 and 12 months (mean 1842 LU/kg per meal, range: 313-3612)
Trial: 29176494
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of proton pump inhibitors (PPIs) exclusively